A Study of IBI363 in Subjects with Advanced Solid Malignancies

This trial is testing a new investigational drug called IBI363 — which combines immunotherapy with another targeted approach — in people with advanced solid tumors (cancers that form solid masses, as opposed to blood cancers). This is an early-phase dose-finding study to assess safety and how the drug behaves in the body. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with an advanced solid tumor cancer - You are in good physical condition (ECOG 0-1) - Your expected survival is at least 3 months - Your bone marrow and organ function are adequate **You may NOT be eligible if...** - You have recently received chemotherapy, targeted therapy, or immune checkpoint inhibitors (within 2–4 weeks) - You have received a live vaccine within 28 days of the first dose - You have unresolved side effects from prior cancer treatment - You have undergone major surgery within the past 4 weeks - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.